John M. Taladay

John M. Taladay is Co-Chair of the Antitrust practice of Baker Botts. He is well-recognized as a leading global antitrust practitioner, known for his work in gaining merger approvals, defending criminal cartel investigations, litigating civil antitrust cases and managing complex international competition matters.

In working closely with the U.S. Federal Trade Commission, the U.S. Department of Justice Antitrust Division, the European Commission and other international agencies, Mr. Taladay has extensive experience in gaining merger clearances particularly in the technology, media, telecommunications, consumer products, software and pharmaceutical sectors and traditional industries including the automotive, airline, primary metals, agriculture, food, chemicals and electronics sectors.

Mr. Taladay has also led the defense of U.S. and foreign corporations and individuals in dozens of major cartel matters including antitrust grand jury investigations into allegations of price fixing, bid-rigging, market allocation and related offenses. He has navigated corporate clients through a range of cartel representation strategies from steadfast defense to leniency application to formal non-prosecution treatment. His litigation work includes acting as lead counsel in numerous civil antitrust class action and other litigation matters involving nearly all aspects of the antitrust laws.

Dr. Walter C. Copan – Congressional Testimony: The State of U.S. Science and Technology: Ensuring U.S. Global Leadership

On February 5th, 2025, Dr. Walter C. Copan testified before the House Committee on Science, Space, and Technology on the State of U.S. Science and Technology: Ensuring U.S. Global Leadership. Copan, Vice President for Research and Technology Transfer at the Colorado School of Mines, former Director of the National Institute
Read More

(Transcript) Protecting Intellectual Property for National Security: A Conversation with Rep. Nathaniel Moran (R-TX)

This transcript is from a CSIS and LeadershIP event hosted on December 3, 2024. Watch the full video here. John J. Hamre: Good afternoon, everybody. Welcome. We’re delighted to have you here. My name is John Hamre. I’m the president at CSIS. And this is going to be one
Read More

Generic Drugs, Property Rights, and the Orange Book

By Chris Borges Intellectual property (IP) rights secured through patents facilitate the introduction of dozens of new brand-name drugs and hundreds of generic drugs annually in the United States. However, proposals advanced by the Biden administration have mistakenly singled out patents as the cause of high drug prices, potentially harming the dense networks
Read More